Records containing: Recurrent Osteosarcoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2022-11-28
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
CLINICAL_TRIALS study record update · 2022-08-25
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry)
CLINICAL_TRIALS study record update · 2022-04-26
A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors
CLINICAL_TRIALS study record update · 2022-03-28
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma
CLINICAL_TRIALS study record update · 2021-05-07
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2021-02-21
Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
CLINICAL_TRIALS study record update · 2020-09-04
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
CLINICAL_TRIALS study record update · 2020-08-10
A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
CLINICAL_TRIALS study record update · 2018-10-15
A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma
CLINICAL_TRIALS study record update · 2018-08-07
A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors
CLINICAL_TRIALS study record update · 2017-09-01
A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma
CLINICAL_TRIALS study record update · 2017-06-05
A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
CLINICAL_TRIALS study record update · 2016-07-22
A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas
CLINICAL_TRIALS study record update · 2016-05-19
Retrospective Study of Genetic Risk Factors for Osteosarcoma
CLINICAL_TRIALS study record update · 2016-05-19
Observational - Tissue Factor Expression in Bone Sarcomas
CLINICAL_TRIALS study record update · 2015-07-30
A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas
CLINICAL_TRIALS study record update · 2015-05-12
Observational - Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma
CLINICAL_TRIALS study record update · 2015-04-15
A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors
CLINICAL_TRIALS study record update · 2015-03-31
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
CLINICAL_TRIALS study record update · 2015-03-30
A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors
CLINICAL_TRIALS study record update · 2014-11-14
Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors
CLINICAL_TRIALS study record update · 2014-03-17
A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma
CLINICAL_TRIALS study record update · 2014-01-30
A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas
CLINICAL_TRIALS study record update · 2013-07-02
A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS
CLINICAL_TRIALS study record update · 2013-06-14
Phase II Trial of Irinotecan in Children With Refractory Solid Tumors